

Synthesis, characterization and biological evaluation of substituted quinazolin-4(3H)-ones as inflammation inhibitors.

Deepak Kumar

Medicinal Chemistry Division, Department of Chemistry, D.N.(P.G.) College, Meerut 250002(U.P), India.

drdeepakkadam18@gmail.com

ABSTRACT: A series of 2-((2-(substituted benzylidene) hydrazinyl methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-ones (**4a-4f**) have been synthesized via condensation of 2-(hydrazinyl methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-one (**3**) with different aromatic aldehydes. Cycloaddition of thioglycolic acid with (**4a-4f**) yielded 3-(naphthalene-2-yl)-4-oxo-3,4-dihydro-quinazolin-2-yl methyl amino)-2-(substituted phenyl) thiazolidin-4-(3H)ones (**5a-5f**), while compound (**4a-4f**) on treatment with chloroacetylchloride in the presence of triethylamine converted into 2-((3-chloro-2-(substituted phenyl)-4-oxoazetidin-1-ylamino) methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-ones (**6a-6f**). The structure of all the newly synthesized compounds have been confirmed by elemental analysis and spectral studies (IR, ¹H-NMR and mass spectroscopy). Compounds (**4a-4f**, **5a-5f** and **6a-6f**) have been evaluated for their anti-inflammatory and analgesic activity and were compared with the standard drug phenylbutazone. The most active compounds of this series are **6c** and **6d**.

KEYWORDS: Quinazolinone, Naphthalene, Thiazolidinone, Azetidinone, anti-inflammatory activity, Analgesic activity, acute toxicity.

INTRODUCTION:

Quinazolinone nucleus has been gaining prominence due to the fact that its derivatives have been found to possess wide spectrum of activities like anti-bacterial^{1,2}, analgesics³, anticonvulsant⁴ and anti-inflammatory⁵⁻¹². However, we have also reported substituted quinazolinone^{13,14} derivatives as potent anti-inflammatory and analgesic inhibitors. Substitution pattern by different aryl or heteroaryl moieties at 2/3 position^{15,16} of quinazolinone nucleus markedly influence anti-inflammatory activities. Moreover, Thiazolidinones¹⁷⁻¹⁹ Azetidinones^{20,21} and Naphthalene^{22,24} are other important pharmacodynamic heterocyclic nuclei which when incorporated in different heterocyclic templates have been reported to possess potent anti-inflammatory activity. In the light of the above observation we have synthesized a new series of quinazolinone derivatives by incorporating the Naphthalene moiety at 2nd while Thiazolidinone and Azetidinone moieties at 3rd position of the quinazolinone nucleus. All the compounds have been screened for their anti-inflammatory, analgesic and ulcerogenic activities.

CHEMISTRY:

2-methyl-4H-benzo [d] [1,3] oxazin-4-one on condensation with β-amino naphthalene give compound **1** which on brominating in the presence of glacial acetic acid resulted into the formation of **2**. The later compound on reaction with hydrazine hydrate yielded compound no. **3**, which on reaction with different substituted aromatic aldehyde in the presence of few drops of acetic acid, gives compound no.

(**4a-4f**). Compound (**4a-4f**) on one hand when reacted with thioglycolic acid in presence of anhydrous ZnCl₂ resulted into, 3-(naphthalene-2-yl)-4-oxo-3,4-dihydro-quinazolin-2-yl methylamino)-2-(substituted phenyl) thiazolidin-4-(3H)ones (**5a-5f**), while compound (**4a-4f**) on cyclocondensation with chloroacetylchloride in the presence of few drops of triethyl amine gives 2-((3-chloro-2-(substituted phenyl)-4-oxoazetidin-1-ylamino)methyl)-3-(naphthalene-2-yl)quinazolin-4(3H)-ones (**6a-6f**).

PHARMACOLOGY

The experiment were performed with albino rats of Charles-Foster strain of either sex, excluding pregnant females, of 60 to 90 days weighing 100 to 120 g. Food (chow pallet) and water was given to the animals *ad libitum*. The test compounds were dissolved in propylene glycol. Indomethacin and phenylbutazone were used as reference drugs for the comparison of anti-inflammatory, analgesic and ulcerogenic activity.

Anti-inflammatory activity against carrageenan-induced rat's paw oedema

This study was done by following the procedure of Winter et al. [1962]. The rats were divided into three groups (control, drug treated, and standard, drug of six animals each. A freshly prepared suspension of carrageenan (1% in 0.9% saline) 0.05 ml. was injected under the planter aponeurosis of the right hind paw of each rat. Test compounds and standard drug were administered orally to the animals of drug treated groups and the standard drug group, respectively 1h before the carrageenan injection. The paw volume of each rat was measured before 1 and after 3 h of carrageenan treatment with the help of a plethymometer. The percent anti-inflammatory activity was calculated according to the formula given below-

$$\text{Percentage of inhibition of oedema} = (1 - V_t/V_c) \times 100$$

Where, V_t and V_c are the mean increase in paw volume of rats of the treated and the control group, respectively. Results obtained were statistically analyzed.

Analgesic activity

Following the method of Berkowitz et al. [1977] performed this activity. This method is based on the property of the test compound to antagonize the phenyl quinone-induced pain syndrome in mice. Groups of five mice were injected intraperitoneally with 0.25 ml of a 0.02% solution of phenylquinone in ethanol (5%) 1 h after of oral administration of the test compound. The number of writhes induced in each mouse was counted for 5 min (between 5 and 10 min) after injection of an irritant. The analgesic effect was expressed as percent protection in comparison to control.

$$\% \text{ protection} = (1 - \text{mean no. of writhes in mice of test groups} / \text{mean number of writhes in mice of control group}) \times 100$$

Ulcerogenic activity

Ulcerogenic liabilities of newly synthesized compounds were checked with method of Verma et al [1981]. Albino rats were fasted for 24 h prior to drug administration. All animals were sacrificed 8 h after drug treatment, and their stomachs and small intestines were microscopically examined to assess the incidence of hyperemia, shedding of epithelium, Petechial and frank hemorrhages and erosion or discrete ulceration with or without perforation. The presence of any one of these criteria was considered to be an evidence of ulcerogenic activity.

Acute Toxicity study

The test compounds were investigated for their acute toxicity (ALD₅₀) in albino mice, according to the method of Smith [1960]. The test compounds were given orally at different dose levels in separate groups of animals. After 24 h of drug administration, percent mortality in each group was observed. ALD₅₀ was calculated from the data obtained.

PHARMACOLOGICAL RESULT AND DISCUSSION

Compounds (**4a-4f**) have shown the varying range (**22.61-34.38%**) of anti-inflammatory activity. Out of these the compound which was substituted by 2-chloro phenyl, i.e **4c** was found to possess good activity (**34.38%**).

Compounds (**5a-5f**), having thiazolidinone ring along with β -amino naphthalene was found to possess varying degree of % of inhibition of oedema i.e. (**27.85-43.66%**). The compounds **5c & 5d**, have exhibited **43.66% 42.48%** of anti-inflammatory activity, which is quite more from its parent corresponding compound **4c** and **4d**. The compounds (**6a-6f**) are characterized by the presence of azetidinone ring (β -lactum) have shown mild to moderate degree of % inhibition of carrageenan induced oedema. i.e. (**36.30-54.26%**).

The compounds, (**6a-6f**) which were characterized by naphthalene ring at 2nd position of quinazolinone ring and azetidinoyl ring at 3rd position of the same ring. However, it

is interestingly enough, that substitution at phenyl ring plays a pivotal role to decide the anti inflammatory activity.

Moreover the compounds which was substituted by 2-chloro and 4-chloro group at phenyl ring, showed **54.26% & 52.54%** activity, which are better than phenyl butazone at a dose of 50 mg/kg p.o.

It is interesting to note that the compounds **6c & 6d** have shown much better activity than phenyl butazone. Considering the potentiality of **6c & 6d** compounds it is thought worthwhile to test this compound was also studied at three graded doses and it was found that at all the three graded doses compounds **6c & 6d** have shown much better activity than reference drug. It is evident from the data that out of the compounds **6c & 6d** have shown promising activity.

The analgesic activities of compounds (**4a-4f**) have shown the varying range (**21.39-32.71%**) of analgesic activity. Out of these, the compound which was substituted by 2-chloro and 4-chloro group at phenyl ring was found to possess good activity (**32.71**). Compound (**5a-5f**) possesses varying degree of % of protection i.e. (**25.24-41.87%**). The compound **5c & 5d** have exhibited **41.87% and 39.18%** of analgesic activity, which is quite more than parent compound **4c & 4d**.

However the compounds (**6a-6f**) have shown range of (**34.10-52.60**) of analgesic activity. The only compound no. **6c** and **6d** have shown better activity than reference drug. Considering the potentiality of the compounds **6c** and **6d** have been screened at three graded doges and found to be better analgesic activity.


The UD₅₀ of compound **6c** is 180 mg/kg p.o. and **6d** is 165 mg/kg p.o., while UD₅₀ of phenyl butazone is 66.6. As the UD₅₀ of compound **6c** and **6d** are quite high then standard drug, which suggest that the compound **6c** and **6d** are less ulcerogenic than phenyl butazone.

The ALD₅₀ of all the compounds were >800 mg/kg i.p. except that of compound **6c & 6d**, which > 1400. As the values of ALD₅₀ is quite high which suggest their good safety margin, **table-V, VI & VII**.

EXPERIMENTAL

All reagents and solvents were generally used as received from the commercial supplier. Reactions were routinely performed in oven-dried borosil glassware. The melting points of compounds were determined in open capillaries with the help of thermionic melting point apparatus and were uncorrected. The progress of the reaction is monitored by TLC and product are purified through recrystallization and purity of the compounds was checked by thin layer chromatography (TLC) performed on silica gel G coated plate of 0.5 mm thickness. The eluent was a mixture of different polar and nonpolar solvents in different proportions, and spots were visualized under iodine chamber. The IR spectra were recorded on Perkin Elmer 881 FTIR spectrophotometer (λ_{max} in cm.). The H-NMR spectra were recorded in CDCl₃ and DMSO-d₆ on Bruker DRX-400/300. FTNMR instrument. Mass spectra were determined on JEOL JMS-D-300 instrument.

Elemental and spectral analyses of the compounds were obtained from sophisticated, Analytical Instrumentation Facility Chandigarh, Punjab and CDRI, Lucknow, India.



2-Methyl-3-(naphthalene-2-yl)-quinazolin-4(3H)-one (1):

A mixture of 2-methyl benzoxazin-4-one (0.01 mole) and 2-amino naphthalene (0.01 mole) in ethanol (50 ml.) were heated under reflux for 2 hr. The excess of solvent was distilled off. The reaction mixture poured onto crushed ice. The solid which was obtained, washed with water, filtered and recrystallized from Ethanol to yield the compound 1.

Compound 1: M.P: 141°C, yield 90%, mol. formula: $C_{19}H_{14}N_2O$

Elemental analysis;

% C :	Calcd. : 79.70	: Found	: 79.88
% H :	Calcd. : 04.93	: Found	: 04.95
% N :	Calcd. : 09.79	: Found	: 09.82

Spectral analysis:

IR (KBr) λ_{max} in cm^{-1} : 2920 (CH_3 , C-H stretching), 3155 (CH-Ar), 1710 ($C=O$ of quinazolinone), 1580 ($C\equiv C$ of aromatic ring), 1240 (C-N).

1H -NMR ($CDCl_3$) \square in ppm: 7.99-6.89 (m, 11H, Ar-H), 2.10 (s, 3H, CH_3).

MS: $[M]^+$ at m/z 286.

2-(Bromomethyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-one (2)

To a solution of compound 1a (0.01 mole) in acetic acid and to this solution bromine (0.04 mole) was added slowly and the mixture was stirred for 8 hr., during this period the

solid was separated. The reaction mixture was poured into ice water and the solid thus obtained was filtered, washed with excess of water. The solid was dried and recrystallized from methanol to yield the compound 2.

Compound 2: M.P.: 182°C, yield 88%, mol. formula: $C_{19}H_{13}BrN_2O$

Elemental analysis:

% C :	Calcd. : 62.48	: Found	: 62.62
% H :	Calcd. : 03.59	: Found	: 03.60
% N :	Calcd. : 07.67	: Found	: 07.70

Spectral analysis :

IR (KBr) λ_{max} in cm^{-1} : 3155 (Ar-CH), 2930 (CH_3 , C-H Stretching), 1710 ($C=O$ of quinazolinone ring), 1540 ($C\equiv C$ of aromatic ring), 1230 (C-N) 705 (C-Br),

1H -NMR ($CDCl_3$) \square in ppm: 7.95-6.85 (m, 11H, Ar-H), 2.25 (s, 2H, CH_2Br)

MS: $[M]^+$ at m/z 365.

2-(Hydrazinyl methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-one (3)

A solution of 2-(bromo methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-one (0.01 mole), hydrazine hydrated (0.01 mole), were taken in acetone (50 ml), The reaction mixture was heated under reflux for 6hr. After cooling it was poured in water and the solid thus obtained was washed with excess of water and recrystallized from ethanol to yield compound 3.

Compound 3: M.P.: 202°C, yield 90%, mol. formula: $C_{19}H_{16}N_4O$

Elemental analysis:

% C :	Calcd. : 72.13	: Found	: 72.42
% H :	Calcd. : 05.10	: Found	: 05.23
% N :	Calcd. : 17.71	: Found	: 17.95

Spectral analysis:

IR (KBr) λ_{max} in cm^{-1} : 3300(N-H), 3165 (Ar-CH), 2925 (CH_3 , C-H Stretching), 1545 ($C\equiv C$ of aromatic ring) 1240 (C-N)

1H -NMR ($CDCl_3$) \square in ppm: 7.90-6.85 (m, 11H, Ar H) 4.80 (brs, 3H, $NH.NH_2$ exchangeable with D_2O), 3.25 (d, 2H, CH_2NH)

MS: $[M]^+$ at m/z 316.

2-((2-(2-Methyl benzylidene) hydrazinyl) methyl)-3-(naphthalene-2-yl) -quinazolin-4(3H)-one (4a):

A mixture of 2-(hydrazinyl methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-one (0.01 mole) and 2-methyl benzaldehyde (0.01 mole) in methanol (50 ml) were heated under reflux for 4hr. The excess of solvent was distilled off. The reaction mixture poured onto crushed ice. The solid which was obtained was washed with water, filtered and recrystallized from mixture of ethanol-water to afford the compound (4a).

Compound 4a: M.P.: 210°C, yield: 85%, mol. Formula: $C_{27}H_{22}N_4O$

Elemental analysis;

% C :	Calcd. : 77.49	: Found	: 77.73
% H :	Calcd. : 05.30	: Found	: 05.31
% N :	Calcd. : 13.39	: Found	: 13.36

Spectral analysis:

IR (KBr) λ_{\max} in cm^{-1} : 3310 (N-H), 3155 (Ar-CH), 2920 (CH_3 , C-H Stretching), 1720 (C=O of quinazolinone ring), 1585 (C=N), 1540 (C \equiv C of aromatic ring), 1244 (C-N).

$^1\text{H-NMR}$ (CDCl_3) \square in ppm: 9.50 (brs, 1H, NHCH_2 exchangeable with D_2O), 8.26 (ss, 1H, N=CH-Ar), 7.85-6.80 (m, 15H, Ar-H), 3.28 (d, 2H, CH_2NH), 2.15 (s, 3H, CH_3).

MS: $[\text{M}]^+$ at m/z 418.

Compounds (**4b-4f**) were prepared similarly and their physical and analytical data are given in **table-I**, while spectral data i.e. IR, $^1\text{H-NMR}$ and mass and given in **table-IV**.

3-(Naphthalene-2-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)methyl amino)-2-o-tolyl thiazolidin-4(3H)-one(**5a**).

To a mixture of 2-(2-(3-methyl benzylidene)hydrazinyl)methyl)-3-(naphthalene-2-yl)quinazolin-4(3H)-one (0.01 mole) and 2-methyl benzaldehyde (0.01 mole) in methanol (50 ml), thioglycolic acid (0.02 mole) was added drop wise in the presence of anhydrous ZnCl_2 and the reaction mixture was refluxed for 10hr. The reaction mixture was concentrated, cooled and poured into ice water, and filtered. The resulting solid was recrystallized from acetic acid to yield the compound (**5a**.)

Compound 5a: M.P.: 255°C , yield: 82%, mol. formula: $\text{C}_{29}\text{H}_{24}\text{N}_4\text{O}_2\text{S}$

Elemental analysis:

% C : Calcd. :	70.71	: Found :	70.55
% H: Calcd. :	04.91	: Found :	04.93
% N : Calcd. :	11.37	: Found :	11.40

Spectral analysis:

IR (KBr) λ_{\max} in cm^{-1} : 3310 (N-H), 3150 (Ar-CH), 2925 (CH_3 , C-H Stretching), 1735 (C=O of thiazolidinone), 1720 (C=O of quinazolinone ring), 1580 (C=N), 1525 (C \equiv C of aromatic ring), 1250 (C-N), 680 (C-S-C)

$^1\text{H-NMR}$ (CDCl_3) \square in ppm: 9.52 (brs, 1H, NHCH_2 exchangeable with D_2O), 7.86-6.83 (m, 15H, Ar-H), 4.52 (s, 1H, CH-Ar), 3.65 (s, 2H, CH_2 of thiazolidinone), 3.29 (d, 2H, CH_2NH), 2.17 (s, 3H, CH_3).

MS: $[\text{M}]^+$ at m/z 492.

Compounds (**5b-5f**) were prepared similarly and their physical and analytical data are given in **table-II**, while spectral data i.e. – IR, $^1\text{H-NMR}$ and mass and given in **table-IV**

2-((3-Chloro-2-(2-o-tolyl azetidino-1-ylamino) methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-one (**6a**);

To a solution of 2-(2-(2-methyl benzylidene)hydrazinyl) methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-one (0.01 mole) and 2-methyl benzaldehyde (0.01 mole) in ethanol (100 ml.), 2-3 drops of triethyl amine and chloroacetyl chloride (0.02 mole) were added under stirring for 1hr. The reaction mixture were stirred and refluxed for 8hr. After refluxing, the reaction mixture was distilled off, cooled and poured onto ice. Solid thus obtained was filtered and recrystallize from acetone to afford compound (**6a**).

Compound 6a: M.P.: 248°C , yield 70%, mol. formula: $\text{C}_{29}\text{H}_{23}\text{ClN}_4\text{O}_2$

Elemental analysis:

% C : Calcd. :	70.37	: Found :	70.48
% H: Calcd. :	04.68	: Found :	04.66
% N : Calcd. :	11.32	: Found :	11.30

Spectral analysis:

IR (KBr) λ_{\max} in cm^{-1} : 3345 (N-H), 3164 (Ar-CH), 3032 (CH-Ar), 2945 (CH_3 , C-H Stretching), 1745 (C=O of thiazolidinone), 1723 (C=O of quinazolinone ring), 1570 (C=N), 1546 (C \equiv C of aromatic ring), 1225 (C-N), 760 (C-Cl).

$^1\text{H-NMR}$ (CDCl_3) \square in ppm: 9.65 (brs, 1H, NHCH_2 exchangeable with D_2O), 7.90-6.88 (m, 15H, Ar-H), 6.64 (s, 1H, CH-Cl), 4.60 (s, 1H, CH-Ar), 3.33 (d, 2H, CH_2NH), 2.22 (s, 3H, CH_3).

MS: $[\text{M}]^+$ at m/z 495.

Compounds (**6b-6f**) were prepared similarly and their physical and analytical data are given in **table-III**, while spectral data i.e.-IR, $^1\text{H-NMR}$ and mass and given in **table-IV**.

REFERENCES

- [1] Alagarsamy V.; Mahukumar V.; Pavalarani N.; Vasanathanathan P.; Rivathi R., Synthesis, analgesic, anti-inflammatory and antibacterial activities of some novel 2,3-disubstituted quinazolin-4(3H)-ones, *Biol. Pharm. Bull.*, **2003**, 26(4): 557-559.
- [2] Alagarsamy V.; Rajesh R.; Rameseshu M.; Vijay K.S.; Ramseshu K.V. and Duraiananda K.T., Synthesis, analgesic, anti- inflammatory and antibacterial activities of some novel 2-methylthio-3-substituted quinazolin-4-(3H)-ones, *Biol. Pharm. Bull.*; **2004**, 27(5): 652-656.
- [3] Amin, K.M.; Kamel M.M.; Anwar M.M.; Khedr M.; Syam Y.M.: Synthesis, biological evaluation and molecular doking of novel series of spiro {(2H, 3H) quinazoline 2,1-cyclohexan] -4 (1H)-one derivatives, *Eur J.med. chem* .**2010**, 45(6) : 2117-2131.
- [4] James F Wolf.; Terry L Ratham.; Merk E Sleevi.; James A Campbell.; Thomas & Greenwood, *J Med Chem.*, **33**(1) **1990**, 16.
- [5] Srivastava, M.; Salahuddin, M.D.; Santra Kumar, S.M.; Synthesis and anti-inflammatory activity of some novel 3-(6- substituted-1, 3, benzothiol-2-yl)- 2 [(4-substituted phenyl) amino} methyl] quinazolins-4 (3H)-ones: *Eur. J. Med.chem.*, **2009**, 6:1055-1062
- [6] Alagarsamy V.; Soloman V.R.; Dhanabal K., Synthesis and pharmacological evaluation of some 3-phenyl-2-substituted- 3H-quinazolin-4-one as analgesic, anti-inflammatory agents, *Bio-Org. Med. Chem.*; **2007**, 15(1): 235-241.
- [7] Bekhit, A.A.; Habib, N.S.; Park, Ji Young: Synthesis of some thiazolyl and thiadiazolyl derivatives of 4-(3H)-quinazolinone as anti-inflammatory, anti-microbial agents: *Bolletino Chemico Farmaceutico*, **2004**, 143(1): 34-39.
- [8] Kumar, Ashok; Rajput, C. S.: Synthesis and anti-inflammatory activity of some newer quinazolins 4-ones derivatives: *Eur.J. Med. Chem*. **2009**, 44(1): 83-90.
- [9] Gupta S.K.; Mishra A., Synthesis, characterization & screening for anti-inflammatory and analgesic activity of

Quinazoline derivatives bearing Azetidinones scaffolds., *Med Chem* **2016** ; 15(1): 31-43.

[10] Wen X.; Wang S.B.; Liu D.C., et.al, Synthesis and evaluation of the anti-inflammatory activity of Quinoline derivatives, *Med Chem Res* **2015**, 24,2591.

[11] Kumar Nallasevam P. et. al, Asian journal of pharmaceutical analysis and medicinal chemistry, 3 (1) **2015**; 31-38.

[12] Kumar D.; Lal R. and Rani S., Synthesis of some new substituted azetidinonyl and thiazolidinonyl quinazolin-4(3H)-ones as potential non-steroidal anti-inflammatory and analgesic agents, *IJIAS*; Vol-08, no.-04, **2014**; 1798-1813.

[13] Kumar, Ashok; Sharma, Shalabh; Kiran, Bajaj; Shipra, Sharma; Hemant, Panwar; Tripti, Singh and Srivastava V.K.: Some new 2,3,6-tri substituted quinazolinones as potent anti-inflammatory, analgesic and COX II inhibitors : *Bioorganic and Medicinal Chemistry*, **2003**, 11: 5293-5299.

[14] Alagarsamy V.; Soloman V.R.; Dhanabal K., Synthesis and pharmacological evaluation of some 3-phenyl-2-substituted- 3H-quinazolin-4-one as analgesic, anti-inflammatory agents, *Bio-Org. Med. Chem.*; **2007**, 15(1): 235-241.

[15] Singh, Inder Pal; Saxena, A.K.; Sinha, J.N.; Bhargava, K.P.; Shanker, K.: Synthesis and anti-inflammatory activity of 2-substitutedphenethyl-3-substitutedphenyl-4(3H)-quinazolinones: *Indian J. Chem.*, **1984**, 23B (6): 592-594.

[16] Khilil M.A.; Soliman R.; Fargaly A M & Bekhit A A, *Arch pharm (Weinheim, Ger.)*, 327(1), **1994**, 27.

[17] Vagdevi H.M.; Vaidya V.P.; Latha K.P.; Padmashali B., Synthesis and pharmacological examination of some thiazolidinone derivatives of naphtho-[2,1-b] furan. *Indian J. Pharma. Sci.*; **2006**, 68 (6): 719-725.

[18] Ottana R.; Maccari R.; Barreca M.L.; Bruno G.; Rotondo A.; Rossi A.; Chiricosta G.; Paola R.D.; Sautebin L.; Cuzzocrea S.; Vigorita M.G., 5-arylidene-2-imino-4-thiazolidinones: Design and synthesis of novel anti-inflammatory agents. *Bio-org. Med. Chem.*; **2005**, 13 (13): 4243-4253.

[19] Yadav R; Srivastava S.D and Srivastava S.K.: Synthesis, anti-microbial and anti-inflammatory activities of 4- oxothiazolidines and their-5-arylidenes: *Indian J. Chem.* **2005**, 44B: 1262-1266.

[20] Tandon, Manju; Kumar, Piyush; Tandon, P.; Bhalla, T.N.; Bhargava, K.P.; Bhargwal, J.P.: Some new azetidinones as possible anti-inflammatory, analgesic and anti-proteolytic agents: *Acta, pharm. Jygosl*, **1983**, 33(2): 93-102.

[21] Doherty, James B.; Finke, Paul E.; Dorn, Conrad P.; Maccoss, Malcolm; Durette, Philippe L.; Mills, Sander G.; Shah, Shrenik K.; Lanza, Thomas J.; Sahoo, Soumya P.: Substituted azetidinones as anti-inflammatory and anti-degenerative agents : *Chem. Abstr.*, **1994**, 121(25): 300749y.

[22] James W.; Barlow, John; j.Walsh: synthesis and evaluation of dimeric 1, 2, 3, 4-tetrahydro naphthalenyl amine and indan-1 ylamine derivatives with mast cell stabilizing and anti-allergic activity. *Eur J.Med chem* **2010**, 45(1) : 25-37.

[23] Parmeshwari K. Halen; Manisha K; Ravat, K. Chagfi, Rajani; Giridhae and Mange R. Yadav *Arch. Pharm. Chem. Life Sci.* **2007**, 340, 88-94.

[24] Sharma, S.T. Singh; R. Mittal; K.K.Saxena. V.K. Srivastava: A study of anti-inflammatory activity of some novel α -amino naphthalene and β -amino naphthalene derivatives *Arch. Pharm. Chem. Life-Sci.* **2006**, 339, 145-152.

[25] Berkowitz R. A.; Finck A. D.; Ngai S. H.; *Pharmacol Exp. Ther.* **1977**, 203,539-547.


[26] Verma, M.; Sinha, J. N.; Gujrati, V. R.; Bhalla, T. N.; Bhargava, K.P.;Shanker, K.: A new potent anti-inflammatory quinazolone: *Pharmacol. Res. Commun.*, **1981**, 13(10): 967-979

[27] Bogert M.T.; and Soil H.A.; *J. Am. Chem. Soc.* **1907**, 29:517.

[28] Winter C. A ; Risley E. A.; and Nuss G. W. : Carrageenan induced oedema in hind paw of the rat as an assay for anti- inflammatory drugs. *Proc. Soc. Exp. Biol. N. Y.* **1962**, 111, 544-550.


[29] Smith Q. E.: Pharmacological Screening Tests Progressive, Medicinal Chemistry, **1960**, Voal. I. Butterworth's, London.1-32.

Table-I: Physical and analytical data of 6-substituted-2-((2-(substituted benzylidene) hydrazinyl methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-ones(4b-4f)




Comp.	R	M.P °C	Yield %	Recrysta- llization solvent	Molecular formula	Elemental analysis					
						% C		% H		% N	
						Calcd.	Found	Calcd.	Found	Calcd.	Found
4b	4-N(CH ₃) ₂	239	76	Acetone	C ₂₈ H ₂₅ N ₅ O	75.15	75.27	05.63	05.62	15.65	15.63
4c	2-Cl	235	80	DMF	C ₂₆ H ₁₉ ClN ₄ O	71.15	71.34	04.36	04.34	12.77	12.75
4d	4-Cl	231	83	Methanol	C ₂₆ H ₁₉ ClN ₄ O	71.15	71.06	04.36	04.38	12.77	12.79
4e	4-OH	228	80	Ethanol	C ₂₆ H ₂₀ N ₄ O ₂	74.27	74.15	04.79	04.80	13.33	13.35
4f	3-NO ₂	233	76	DMF	C ₂₆ H ₁₉ N ₅ O ₃	69.48	69.26	04.26	04.25	15.58	15.60

Table-II: Physical and analytical data of 6-substituted-3-(naphthalene-2-yl)-4-oxo-3,4-dihydro-quinazolin-2-yl) methyl amino)-2-(substituted phenyl) thiazolidin-4-(3H)ones (5b-5f)



Comp.	R	M.P °C	Yield %	Recrysta- llization Solvent	Molecular Formula	Elemental analysis %					
						% C		% H		% N	
						Calcd.	Found	Calcd.	Found	Calcd.	Found
5b	4-N(CH ₃) ₂	244	72	Ethanol	C ₃₀ H ₂₇ N ₅ O ₂ S	69.08	69.13	5.22	5.23	13.43	.38
5c	2-Cl	248	74	Ethanol	C ₂₈ H ₂₁ ClN ₄ O ₂ S	65.55	65.51	4.13	4.16	10.92	10.95
5d	4-Cl	257	79	Acetic Acid	C ₂₈ H ₂₁ ClN ₄ O ₂ S	65.55	65.50	4.13	4.15	10.92	10.96
5e	4-OH	259	74	DMF- water	C ₂₈ H ₂₂ N ₄ O ₃ S	68.00	68.25	4.48	4.45	11.33	11.29
5f	3-NO ₂	263	70	Methanol	C ₂₈ H ₂₁ N ₅ O ₄ S	64.23	64.34	4.04	4.02	13.38	13.35

Table-III: Physical and analytical data of 6-substituted-2-((3-chloro-2-(substituted phenyl)-4-oxoazetidin-1-ylamino) methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-ones (6b-6f)




Comp.	R	M.P °C	Yield %	Recrysta -lization solvent	Molecular Formula	Elemental analysis %					
						% C		% H		% N	
						Calcd	Found	Calcd	Found	Calcd	Found
6b	4-N(CH ₃) ₂	270	65	DMF water	C ₃₀ H ₂₆ ClN ₅ O ₂	68.76	68.58	05.00	05.01	13.36	13.37
6c	2-Cl	259	68	DMF water	C ₂₈ H ₂₀ Cl ₂ N ₄ O ₂	65.25	65.38	03.91	03.92	10.87	10.90
6d	4-Cl	265	71	DMF water	C ₂₈ H ₂₀ Cl ₂ N ₄ O ₂	65.25	65.29	03.91	03.90	10.87	10.90
6e	4-OH	262	62	Ethanol	C ₂₈ H ₂₁ ClN ₄ O ₃	67.67	67.52	04.26	04.27	11.27	11.29
6f	3-NO ₂	252	58	Acetone	C ₂₈ H ₂₀ ClN ₅ O ₄	63.94	63.99	03.83	03.82	13.32	13.30

Table-IV: Spectral Data of compounds (4b-4f), 5b-5f), & (6b-6f).

Comp	IR (KBr)v _{max} in cm ⁻¹	¹ H-NMR (CDCl ₃) δ in ppm	MS:[M] ⁺ m/z
4b	3310 (N-H), 3160 (Ar-CH), 2920 (CH ₃ , C-H stretching), 1725 (C=O of quinazolinone ring), 1580 (C=N), 1525 (C≡C of aromatic ring), 1240 (C-N).	9.49 (brs, 1H, NHCH ₂), 8.24 (ss, 1H, N=CH-Ar), 7.83-6.80 (m, 15H, Ar-H), 3.26 (d, 2H, CH ₂ NH), 1.25 (s, 6H, Ar-N (CH ₃) ₂)	434
4c	3320 (N-H), 3160 (Ar-CH), 2930 (CH ₃ , C-H stretching), 1720 (C=O of quinazolinone ring), 1580 (C=N), 1530 (C≡C of aromatic ring), 1235 (C-N), 740 (C-Cl).	9.54 (brs, 1H, NHCH ₂), 8.27 (ss, 1H, N=CH-Ar), 7.88-6.87 (m, 15H, Ar-H), 3.29 (d, 2H, CH ₂ NH)	420
4d	3325 (N-H), 3165 (Ar-CH), 2935 (CH ₃ , C-H stretching), 1725 (C=O of quinazolinone ring), 1585 (C=N), 1535 (C≡C of aromatic ring), 1240 (C-N), 735 (C-Cl).	9.53 (brs, 1H, NHCH ₂), 8.25 (ss, 1H, N=CH-Ar), 7.87-6.85 (m, 15H, Ar-H), 3.27 (d, 2H, CH ₂ NH)	450
4e	3315 (N-H), 3165 (Ar-CH), 2925 (CH ₃ , C-H stretching), 1720 (C=O of quinazolinone ring), 1575 (C=N), 1525 (C≡C of aromatic ring), 1240 (C-N).	9.52 (brs, 1H, NHCH ₂), 9.22 (ss, 1H, OH), 8.26 (ss, 1H, NH=CH-Ar), 7.85-6.75 (m, 15H, Ar-H), 3.29 (d, 2H, CH ₂ NH)	449
4f	3310 (N-H), 3155 (Ar-CH), 2920 (CH ₃ , C-H stretching), 1720 (C=O of	9.51 (brs, 1H, NHCH ₂), 8.25 (ss, 1H, N=CH-Ar), 7.84-6.79 (m,	448


	quinazolinone ring), 1590 (C=N) 1530 (C≡C of aromatic ring), 1230 (C-N).	15H, Ar-H), 3.26 (d, 2H, CH ₂ NH)	
5b	3330 (N-H), 3145 (Ar-CH), 2930 (CH ₃ , C-H stretching), 1735 (C=O of thiazolidinone), 1715 (C=O of quinazolinone ring), 1560 (C=N), 1530 (C≡C of aromatic ring), 1215 (C-N), 665 (C-S-C).	9.56 (brs, 1H, NHCH ₂), 7.83-6.82 (m, 15H, Ar-H), 4.54 (s, 1H, CH-Ar) 3.65 (s, 2H of thiazolidinone), 3.30 (d, 2H, CH ₂ NH), 1.25 (s, 6H, Ar-N(CH ₃) ₂)	522
5c	3345 (N-H), 3165 (Ar-CH), 2950 (CH ₃ , C-H stretching), 1745 (C=O of thiazolidinone), 1725 (C=O of quinazolinone ring), 1570 (C=N), 1535 (C≡C of aromatic ring), 1225 (C-N), 750 (C-Cl), 675 (C-S-C).	9.64 (brs, 1H, NHCH ₂), 7.88-6.86 (m, 15H, Ar-H), 4.50 (s, 1H, CH-Ar) 3.70 (s, 2H of thiazolidinone), 3.37 (d, 2H, CH ₂ NH)	513
5d	3335 (N-H), 3155 (Ar-CH), 2930 (CH ₃ , C-H stretching), 1740 (C=O of thiazolidinone), 1720 (C=O of quinazolinone ring), 1530 (C≡C of aromatic ring), 1570 (C=N), 1225 (C-N), 735 (C-Cl), 670 (C-S-C).	9.60 (brs, 1H, NHCH ₂), 7.84-6.77 (m, 15H, Ar-H), 4.48 (s, 1H, CH-Ar) 3.68 (s, 2H of thiazolidinone), 3.35 (d, 2H, CH ₂ NH)	513
5e	3335 (N-H), 3160 (Ar-CH), 2930 (CH ₃ , C-H stretching), 1735 (C=O of thiazolidinone), 1725 (C=O of quinazolinone ring), 1570 (C=N), 1535 (C≡C of aromatic ring), 1230 (C-N), 670 (C-S-C).	9.54 (brs, 1H, NHCH ₂), 9.30 (s, 1H, OH), 7.83-6.77 (m, 15H, Ar-H), 4.51 (s, 1H, CH-Ar) 3.64 (s, 2H, CH ₂ of thiazolidinone), 3.30 (d, 2H, CH ₂ NH)	495
5f	3330 (N-H), 3150 (Ar-CH), 2925 (CH ₃ , C-H stretching), 1740 (C=O of thiazolidinone), 1715 (C=O of quinazolinone ring), 1560 (C=N), 1530 (C≡C of aromatic ring), 1225 (C-N), 665 (C-S-C).	9.53 (brs, 1H, NHCH ₂), 7.86-6.85 (m, 15H, Ar-H), 4.50 (s, 1H, CH-Ar) 3.62 (s, 2H, CH ₂ of thiazolidinone), 3.30 (d, 2H, CH ₂ NH)	524
6b	3350 (N-H), 3140 (Ar-CH), 3025 (CH-Ar), 2940 (CH ₃ , C-H stretching), 1735 (C=O of Azetidinone), 1715 (C=O of quinazolinone ring), 1560 (C=N), 1530 (C≡C of aromatic ring), 1220 (C-N), 750 (C-Cl).	9.64 (brs, 1H, NHCH ₂), 7.88-6.84 (m, 15H, Ar-H), 6.63 (s, 1H, CH-Cl), 4.58 (s, 1H, CH-Ar), 3.30 (d, 2H, CH ₂ NH), 1.26 (s, 6H, Ar-N (CH ₃) ₂)	524
6c	3375 (N-H), 3165 (Ar-CH), 3040 (CH-Ar), 2960 (CH ₃ , C-H stretching), 1765 (C=O of Azetidinone), 1740 (C=O of quinazolinone ring), 1575 (C=N), 1545 (C≡C of aromatic ring), 1240 (C-N), 770 (C-Cl).	9.75 (brs, 1H, NHCH ₂), 7.92-6.88 (m, 15H, Ar-H), 6.73 (s, 1H, CH-Cl), 4.69 (s, 1H, CH-Ar), 3.40 (d, 2H, CH ₂ NH)	515
6d	3370 (N-H), 3150 (Ar-CH), 3040 (CH-Ar), 2960 (CH ₃ , C-H stretching), 1760 (C=O of Azetidinone), 1730 (C=O of quinazolinone ring), 1565 (C=N), 1530 (C≡C of aromatic ring), 1240 (C-N), 765 (C-Cl).	9.73 (brs, 1H, NHCH ₂), 7.90-6.85 (m, 15H, Ar-H), 6.71 (s, 1H, CH-Cl), 4.66 (s, 1H, CH-Ar), 3.39 (d, 2H, CH ₂ NH)	515
6e	3340 (N-H), 3155 (Ar-CH), 3030 (CH-Ar), 2945 (CH ₃ , C-H stretching), 1740 (C=O of Azetidinone), 1725 (C=O of quinazolinone ring), 1560 (C=N), 1525 (C≡C of aromatic ring), 1230 (C-N), 750 (C-Cl).	9.68 (brs, 1H, NHCH ₂), 7.96-6.91 (m, 15H, Ar-H), 6.69 (s, 1H, CH-Cl), 4.64 (s, 1H, CH-Ar), 3.36 (d, 2H, CH ₂ NH), 9.28 (ss, 1H, OH)	497
6f	3355 (N-H), 3160 (Ar-CH), 3040 (CH-Ar), 2960 (CH ₃ , C-H stretching), 1745 (C=O of Azetidinone), 1730 (C=O of quinazolinone ring), 1550 (C=N), 1535 (C≡C of aromatic ring), 1235 (C-N), 755 (C-Cl).	9.62 (brs, 1H, NHCH ₂), 7.87-6.82 (m, 15H, Ar-H), 6.63 (s, 1H, CH-Cl), 4.66 (s, 1H, CH-Ar), 3.35 (d, 2H, CH ₂ NH)	526

Table-V: Biological data of 2-((2-(substituted benzylidene) hydrazinyl methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-ones (4a-4f)



Comp.	R	Anti-inflammatory Activity		Analgesic Activity		UD ₅₀ (mg./kg. i.p)	Acute Toxicity ALD ₅₀ (mg./kg.p.o)
		Dose (mg./kg. p.o)	% Inhibition of oedema	Dose (mg./kg.p.o)	% Protection		
4a	2-CH ₃	50	26.16*	50	24.48*		>800
4b	4-N(CH ₃) ₂	50	27.15*	50	25.82*		>800
4c	2-Cl	50	34.38*	50	32.71*		>800
4d	4-Cl	50	32.43*	50	30.18*		>800
4e	4-OH	50	22.61*	50	21.39*		>800
4f	3-NO ₂	50	24.36*	50	23.24*		>800


Table-VI: Biological data of 3-(naphthalene-2-yl)-4-oxo-3,4-dihydro-quinazolin-2-yl) methyl amino)-2-(substituted phenyl) thiazolidin-4-(3H)ones (5a-5f)



Comp.	R	Anti-inflammatory Activity		Analgesic Activity		UD ₅₀ (mg./kg.i.p)	Acute Toxicity ALD ₅₀ (mg./kg.p.o)
		Dose (mg./kg.p.o)	% Inhibition of oedema	Dose (mg./kg.p.o)	% Protection		
5a	2-CH ₃	50	36.23*	50	34.71*	-	>800
5b	4-N(CH ₃) ₂	50	35.49*	50	33.68*	-	>800
5c	2-Cl	50	43.66**	50	41.87**	-	>800

5d	4-Cl	50	42.48**	50	39.18*	-	>800
5e	4-OH	50	28.78*	50	26.56*	-	>800
5f	3-NO ₂	50	27.85*	50	25.24*	-	>800

Table-VII: Biological data of 2-((3-chloro-2-(substituted phenyl)-4-oxoazetidin-1-ylamino) methyl)-3-(naphthalene-2-yl) quinazolin-4(3H)-ones (6a-6f)



Comp.	R	Anti-inflammatory Activity		Analgesic Activity		UD ₅₀ (mg./kg.i.p)	Acute Toxicity ALD ₅₀ (mg./kg.p.o)
		Dose (mg./kg.p.o)	% Inhibition of oedema	Dose (mg./kg.p.o)	% Protection		
6a	2-CH ₃	50	40.65**	50	39.32*	-	>800
6b	4-N(CH ₃) ₂	50	42.40**	50	40.55**	-	>800
6c	2-Cl	50	54.26***	50	52.60***	180	>1400
6d	4-Cl	50	52.54***	50	51.40***	-	>1400
6e	4-OH	50	36.30**	50	36.45**	-	>800
6f	3-NO ₂	50	38.56**	50	34.10**	-	>800
Pheny butazone		25	17.50**	25	15.80**	66.6	
		50	38.80***	50	36.50***		
		100	68.60***	100	60.50***		

*P<0.05, **P<0.01, ***<0.001

Propylene glycol standard for control group.